Guselkumab (Tremfya, Johnson & Johnson) Inhibits Progression of Joint Damage in PsA
Guselkumab (Tremfya, Johnson & Johnson) inhibited progression of joint structural damage in active psoriatic arthritis (PsA) at 24 weeks compared to placebo, according to the Phase 3b APEX study presented at the European Alliance of Associations for Rheumatology (EULAR) 2025 Congress in Barcelona, Spain.